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ABSTRACT
Neutrophil alloantigens are involved in a variety of clinical conditions including immune neutropenias, transfusion-
related acute lung injury (TRALI), refractoriness to granulocyte transfusions and febrile transfusion reactions. In
the last decade, considerable progress has been made in the characterization of the implicated antigens. Currently,
seven antigens are assigned to five human neutrophil antigen (HNA) systems. The HNA-1a, HNA-1b and HNA-1c
antigens have been identified as polymorphic forms of the neutrophil Fcγ receptor IIIb (CD16b), encoded by three
alleles. Recently, the primary structure of the HNA-2a antigen was elucidated and the HNA-2a-bearing glycoprotein
was identified as a member of the Ly-6/uPAR superfamily, which has been clustered as CD177. The HNA-3a antigen is
located on a 70-95 kDa glycoprotein; however, its molecular basis is still unknown. Finally, the HNA-4a and HNA-5a
antigens were found to be caused by single nucleotide mutations in the αM (CD11b) and αL (CD11a) subunits ofthe leucocyte adhesion molecules (β2 integrins). Molecular and biochemical characterization of neutrophil antigenshave expanded our diagnostic tools by the introduction of genotyping techniques and immunoassays for antibody
identification. Further studies in the field of neutrophil immunology will facilitate the prevention and management of
transfusion reactions and immune diseases caused by neutrophil antibodies.
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DEFINITION AND CLASSIFICATION
Since the beginning of the twentieth century, investiga-
tors have observed that the sera of some patients caused
agglutination of leucocytes from others individuals.
Granulocyte antibodies have been detected in sera of
multitransfused persons, women after pregnancy, pa-
tients with neutropenia, patients with febrile transfusion
reactions, and in the blood of donors that caused pul-
monary transfusion reactions in the transfusion recipi-
ent. The first granulocyte-specific antigen was described
in 1960 by Lalezari in a case of neonatal alloimmune neu-
tropenia. Meanwhile, a number of granulocyte antigens
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has been described and characterized on the biochemical
and molecular level, which allowed the development of
assays for rapid antibody identification and DNA-based
techniques for antigen typing (Bux et al. 1995).
Neutrophil antibodies have been shown to play a key
role in the patophysiology of several clinical conditions,
including neonatal alloimmune neutropenia (NAN), au-
toimmune neutropenia of childhood, febrile non-hemo-
lytic transfusion reactions (FNHTR), transfusion-related
acute lung injury (TRALI), immune neutropenia after
bone-marrow transplantation, transfusion-related allo-
immune neutropenia (TRAIN), drug-induced neutrope-
nia, and refractoriness to granulocyte transfusion. The
identification of neutrophil antigens and antibodies is
relevant for the diagnosis of these disorders (Table I).
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TABLE IClinical conditions associated with neutrophil antibodies.
Alloimmune diseases Autoimmune diseases
Neonatal alloimmune neutropenia (NAN) Autoimmune neutropenia of childhood
Transfusion-related acute lung Drug-induced immune neutropeniainjury (TRALI)
Alloimmune neutropenia after Autoimmune neutropenia after
bone marrow transplantation bone marrow transplantation
Transfusion-related alloimmune
neutropenia (TRAIN)
Refractoriness to granulocyte transfusions
Febrile transfusion reactions
TABLE IIISBT Human neutrophil alloantigens (HNA) nomenclature.
Antigen system Carrier glycoproteins CD Antigens Former names Alleles
HNA-1a NA1 FCGR3B*01
HNA-1 Fcγ Receptor IIIb CD16b HNA-1b NA2 FCGR3B*02
HNA-1c SH FCGR3B*03
HNA-2 NB1 glycoprotein CD177 HNA-2 NB1 CD177*01
HNA-3 unknown (GP 70–95) HNA-3a 5b unknown
HNA-4 MAC-1; CR3; αMβ2-integrin CD11b HNA-4a MART ITGAM*01 (230G)HNA-5 LFA-1; αLβ2-integrin CD11a HNA-5a OND ITGAL*01 (2372G)
There are several clinically important human neu-
trophil alloantigen systems. The nomenclature used for
these antigens was established in 1998 by an Interna-
tional Society of Blood Transfusion (ISBT) Working
Party (Bux 1999) (Table II). The antigen systems are
referred to as human neutrophil antigens (HNA). This
nomenclature is based on the glycoprotein location of
the antigens. Different polymorphisms of the same gly-
coprotein are designated alphabetically, in a sequential
order of detection (HNA-1a, -1b, -1c) and the nomen-
clature of the alleles named according to the Guidelines
of the International Workshop on Human Gene Map-
ping. Currently, the HNA systems comprise seven anti-
gens, which are assigned to five glycoproteins (antigen
systems).
HNA-1
BIOCHEMISTRY AND MOLECULAR BASIS
The best characterized neutrophil antigen system is
HNA-1, which has three alleles, HNA-1a, -1b e -1c.
HNA-1a and -1b were the first granulocyte antigens
described in cases of alloimune neonatal neutropenia
(Lalezari et al. 1960). Later on, a third polymorphism
was described, the SH antigen, now called HNA-1c (Bux
et al. 1997b). HNA-1 alloantibodies can cause alloim-
mune neonatal neutropenia, TRALI and seem not to af-
fect engraftment and neutrophil recovery in alloimmu-
nized recipients of bone marrow transplants (Bux 2001)
(Table III).
HNA-1 antigens are located on the human neutro-
phil Fc gamma-receptor IIIb (FcγRIIIb) and encoded by
the FCGR3B gene located on chromosome 1. FcγRIIIb
belongs to the immunoglobulin superfamily, as it has
two extracellular disulphide-bonded immunoglobulin G
(IgG)-like domains. The membrane proximal domain
contains residues which are critical for ligand binding
(Hibbs et al. 1994), and the function of the distal domain
is unknown, but it is quite polymorphic. Monoclonal
antibodies reacting with FcRIIIb have been designated
as CD16b. The FcγRIIIb is attached to the granulo-
cyte membrane through a glycosyl-phosphatidylinositol
(GPI) anchor that gives the receptor a high lateral mo-
bility in the outer leaflet of the phospholipids bilayer
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TABLE IIIClinical disorders caused by neutrophil specific antibodies.
Antibody Clinical condition
Alloimmune neonatal neutropenia
HNA-1 Autoimmune neutropenia
TRALI
Alloimmune neonatal neutropenia
Autoimmune neutropenia
HNA-2a TRALI
Drug-induced neutropenia
Graft failure after bone marrow transplantation
HNA-3a TRALI
HNA-4a Alloimmune neonatal neutropeniaAutoimmune neutropenia
HNA-5a Unknown
of the plasma membrane (Huizinga et al. 1990a). The
FcγRIIIb is a heavily glycosylated protein with different
relative molecular weights of 50-65 kDa and 65-80 kDa
for the HNA-1a and -1b isoforms, respectively (Ory et
al. 1989).
FcγRIIIb is the clinically most important immuno-
genic glycoprotein of the neutrophil membrane. In addi-
tion, 30% of granulocyte autoantibodies recognize epi-
topes on the FcγRIIIb with a preferential binding to
the HNA-1a polymorphic form of this receptor (Bux et
al. 1997a). The glycoprotein is constitutively only ex-
pressed on neutrophils in mean copy numbers of 190.000
(range 120.000-400.000) (Huizinga et al. 1989).
The FCGR3B gene is located on the long arm of
the chromosome 1 and consists of five exons with 699
bp encoding 233 amino acids, including a signal peptide
of 17 amino acids. cDNA analysis of the gene revealed
five nucleotide substitutions (nucleotides 141, 147, 227,
277 and 349) associated with the HNA-1a/b polymor-
phisms. All substitution sites are located in the third
exon that codes for the membrane distal domain. The
five nucleotide differences result in four amino acid sub-
stitutions (positions 36, 65, 82 and 106) with two addi-
tional N-linked glycosilation sites, so that the HNA-1b
polymorphic form of the FCGR3B has six potential N-
linked glycosilation sites, compared to four of the HNA-
1a isoform. This explains the observed differences in
their relative molecular weights (Ravetch and Perussia
1989).
An additional polymorphism of the FCGR3B is the
HNA-1c antigen that has been associated with a later sin-
gle nucleotide substitution in the allele encoding HNA-
1b (Bux et al. 1997a). HNA-1c genetics is complicated
by the fact that some of the HNA-1c-positive individu-
als, mainly Europeans, possess three FCGR3B genes in
their genome with a HNA-1a and -1c allele combination
on the chromosome (Koene et al. 1998). An unequal
crossing-over event during meiosis may be the reason
for FCGR3B gene duplication in which the allele encod-
ing HNA-1a became associated with the HNA-1c allele
(Steffensen et al. 1999).
In contrast to individuals with a hiperexpression of
the FcγRIIIb, few individuals do not express this recep-
tor on their neutrophils due to FCGR3B gene deficiency,
showing the HNA-1 null phenotype (de Haas et al. 1995).
Most of the FcγRIIIb deficient individuals do not suffer
from repeated infections, autoimmune or immune com-
plex diseases, but pregnant women can form FcγRIIIb-
specific alloantibodies causing alloimmune neutropenia
in the neonate (Huizinga et al. 1990b).
FUNCTION
The FcγRIIIb is a low affinity receptor for IgG1 and
IgG3. It binds with its membrane proximal domain to
the Fc parts of polymeric IgG antibodies. Resting neu-
trophils primarily engage FcγRIIIb for the binding of
immune complexes and clearing them from the circula-
tion. The receptor contributes also to the phagocytosis
of opsonized micro-organisms (Bux 2008).
FREQUENCY
The HNA-1 frequencies vary widely among different
populations (Kuwano et al. 2000, Kissel et al. 2000,
Lin et al. 1994, Ohto and Matsuo 1989, Han and Um
1997). Using flow cytometry technique to phenotype
randomly healthy Brazilian blood donors, we found a
frequency of 65% and 83% for HNA-1a and HNA-1b,
respectively (Norcia et al. 2006) (Table IV).
HNA-2
BIOCHEMISTRY AND MOLECULAR BASIS
The HNA-2a antigen was described as neutrophil-spe-
cific antigen ‘NB1’ by Lalezari and co-workers in 1971
(Lalezari et al. 1971). HNA-2a is exclusively expressed
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TABLE IVHuman neutrophil alloantigens (HNA) frequencies (%).
Population HNA-1a HNA-1b HNA-1c HNA-1 null HNA-2a HNA-3a HNA-4a HNA-5a
Africans 46–66 78–84 23–31 4 98 NT NT 88
Chinese 90 52 0 0–0.2 99 NT NT 65
Asian Indians 44 83 16 NT NT NT NT NT
Japanese 88 51–61 0 < 0.4 89–99 NT NT NT
Koreans 78 75 < 1 NT 86 NT 99 96
Europeans 54–52 87–89 5–7 0.2–0.8 87–97 89–99 96 96
North Americans 56–62 89 5 NT 97 NT NT 96
Brazilian 100 83 11 NT 97 86–95 96 91
Brazilian Indians 83 36 0 NT NT NT 100 96
NT: not tested.
on neutrophils and can be found on the plasma mem-
brane and membranes of secondary granules and secre-
tory vesicles (Goldschmeding et al. 1992). An unique
characteristic of HNA-2a is its heterogenous expression,
i.e. a single individual has a neutrophil subpopulation
which expresses HNA-2a and another that does not.
The mean proportion of neutrophils that express HNA-
2a ranges from 0-100% and is slightly greater in fe-
males (63%) than in males (53%) (Matsuo et al. 2000,
Moritz et al. 2007). The HNA-2a expression has been
reported to drop in older women but not in men, suggest-
ing that estrogen may influence the antigen expression.
This is in accordance with the finding that the HNA-
2a expression increases in pregnancy (Caruccio et al.
2003). HNA-2a-negative individuals and the negative
neutrophil subset of HNA-2a-positive individuals show
in fact a null phenotype since their neutrophils are de-
ficient in the carrier glycoprotein (Kissel et al. 2002).
The alloantibodies formed by HNA-2a-negative individ-
uals are important in neonatal alloimmune neutropenia,
TRALI, autoimmune drug-induced neutropenia, and
graft failure after bone marrow transplantation.
HNA-2a has been characterized as a 56-64 kDa
glycoprotein, which is like the FcγRIIIb linked to the
cell membrane via a GPI anchor (Stroncek et al. 1990).
Monoclonal antibodies directed against HNA-2a have
been clustered as CD177. The glycoprotein has two
cysteine-rich domains and three N-linked glycosylation
sites. Homology of the cysteine-rich domains suggests
that CD177 belongs to the Ly-6/uPAR/snake-toxin fam-
ily of proteins (Kissel et al. 2001).
Kissel et al. (2001) sequenced the gene encoding
HNA-2a and found it to be located on chromossome
19q13.2. In addition, there is a pseudogene homolo-
gous to exons 4 through 9 that is located adjacent to
the HNA-2a gene, but oriented in the opposite direction.
The HNA-2a cDNA consist of 1311 bp coding for 437
amino acids, including a signal peptide of 21 amino acids.
The HNA-2a null phenotype was found to be the result
of incorrect splicing, leading to mRNA strands contain-
ing intron sequences with stop codons.
FUNCTION
CD177 is involved in the adhesion of neutrophils to en-
dothelial cells and their transendothelial migration by
cationic-dependent interaction with the heterophilic do-
mains of PECAM-1 (CD31) (Sachs et al. 2007). Re-
cently, it has been demonstrated that the subset of neu-
trophils that express CD177 on their plasma membrane
also displays the neutrophil serine protease proteinase 3
(mPR3), which is usually located intracellularly. The
function of this co-expression of CD177 and mPR3 on
the plasma membrane of a neutrophil subset is unknown
(Bauer et al. 2007).
A highly significant HNA-2a up-regulation was ob-
served in patients with bacterial infections and poly-
cytemia vera, as well as in stem cells donors stimulated
with granulocyte colony-stimulating factor (Göhring et
al. 2004).
FREQUENCY
HNA-2a is a high frequency antigen in North Americans,
Europeans (97%) and Japanese (89-99.5%). Phenotyp-
ing studies performed in our laboratory employing flow
cytometry have shown that the frequency of HNA-2a in
Brazilians is similar to that described by North Ameri-
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can and European studies (Lalezari et al. 1971, Moritz
et al. 2007, Norcia et al. 2006, Ohto and Matsuo 1989,
Tanigushi et al. 2002) (Table IV).
HNA-3
BIOCHEMISTRY AND MOLECULAR BASIS
HNA-3a antigen has been introduced by van Leeuwen
et al. in 1964. It has been suggested that the anti-
gen is located on a 70- to 95 kDa protein, which is not
linked to the plasma membrane via a GPI anchor as the
HNA-1 and -2 antigens (de Haas et al. 2000). Cyto-
genetics studies suggested that the HNA-3a antigen is
the product of a gene located on the chromossome 4.
However, the primary structure of HNA-3 remains to
be elucidated.
HNA-3a is expressed on neutrophils and lympho-
cytes, whereas the reported expression on platelets is
controversial. Alloantibodies to HNA-3a were found in
occasional cases of febrile transfusion reactions (Lale-
zari and Bernard 1965) and neonatal immune neutrope-
nia (de Haas et al. 2000). HNA-3a alloantibodies were
increasingly reported in conjunction with TRALI, espe-
cially with severe cases, in which patients required arti-
ficial ventilation, or with fatal reactions (Davoren et al.
2003). This is possibly the result of the neutrophil prim-
ing capacity for reactive oxygen species production, and
probably the marked capability of the HNA-3a antibod-
ies to agglutinate neutrophils.
FUNCTION
Nothing is known about the function of HNA-3a.
FREQUENCY
HNA-3a is a high frequency antigen with reported phe-
notype frequencies ranging from 89-99% in Europeans
(van Leeuwen et al. 1964, de Haas et al. 2000, Lalezari
and Bernard 1965). Using flow cytometry technique, we
found a HNA-3a frequency of 95% in randomly inves-
tigated healthy Brazilian blood donors (Norcia et al.
2006) (Table IV).
HNA-4
BIOCHEMISTRY AND MOLECULAR BASIS
The HNA-4a antigen and the identification of HNA-
4a-negative individuals were first reported in 1986 by
Kline et al.
The HNA-4 system is located on the β2-integrin,a member of the Leu-CAM family and integrin super-
family, which shares a common β subunit (β2 or CD18)noncovalently associated with four different α subunits.
The HNA-4a antigen is a polymorphic variant of αM(CR3; CD11b) subunit as the result of a single nucleo-
tide change G302A, leading to an arginine instead of a
histidine at position 61 (Simsek et al. 1996). HNA-4a
alloantibodies can cause neonatal immune neutropenia
(Fung et al. 2003). Two types of HNA-4a antisera have
been identified, with different effects in cell interac-
tions, suggesting that the humoral response to this anti-
gen is heterogeneous and differs from one immunized
person to another (Sachs et al. 2004). The CD11b/CD18
is also the target of autoantibodies reported not only to
cause neutropenia, but also to be able to impair neu-
trophil adhesion (Hartman and Wright 1991).
FUNCTION
CD11b/CD18, also known as Mac-1, CR3 or αMβ2-integrin, is expressed on neutrophils, monocytes and
natural killer cells, and plays an important role in the
leukocyte adhesion to endothelial cells and platelets, as
well as in phagocytosis. It is not known whether the
function of CD11b/CD18 is influenced by the HNA-4a
polymorphism.
FREQUENCY
HNA-4a genotypes were found in > 90% of whites,
Asians and Brazilians (Kline et al. 1986, Han and Han
2006, Cardone et al. 2006) (Table IV).
HNA-5
BIOCHEMISTRY AND MOLECULAR BASIS
The existence of a leukocyte non-HLA, now termed
HNA-5a, defined by antibodies in a serum named
‘OND’, was reported by Decary et al. in 1979. HNA-
5a has been located on the αL (CD11a; LFA-1) chainof the leukocyte β2-integrin family, and was found tobe due to a G2466C substitution in the coding sequence
predicting the amino acid change Arg776Thr (Simsek
et al. 1996). HNA-5a alloantibodies have not yet been
involved in neutropenia.
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FUNCTION
The CD11a/CD18 complex, also known as LFA-1 or
αMβ2-integrin, is expressed on all leucocytes and func-tion as a leucocyte adhesion molecule. It is unknown
whether the integrin function is influenced by the HNA-
5a polymorphism.
FREQUENCY
Genotyping resulted in HNA-5a frequencies between
79% and 88% in different populations (Sachs et al.
2005). We have found a higher frequency of HNA-5a
positive genotype in Brazilian blood donors (91%), and
Brazilian Amazon Indians (96%) (Cardone et al. 2006)
(Table IV).
LABORATORIAL ASSAYS FOR DETECTING NEUTROPHIL
ANTIGENS AND ANTIBODIES
PHENOTYPING AND GENOTYPING
OF NEUTROPHIL ANTIGENS
Traditionally, neutrophil antigen phenotyping has been
performed using human alloantibodies in the granulocyte
agglutination test (GAT), or the granulocyte immunoflu-
orescence test (GIFT). However, alloantisera specific to
neutrophil antigens are not always available. Alloan-
tibodies to HNA-1a, -1b, -2a, and -3a are available, but
antibodies to HNA-1c, -4a, and -5a are difficult to obtain.
We have found that, when used in flow cytometry,
the neutrophil alloantibodies allow a higher sensitivity
rate do detect HNAs when compared to the GIFT (A.M.
Norcia et al., unpublished data). The GAT and GIFT
assays require training, as the results are evaluated with
a microscope rather than by the flow cytometer.
Monoclonal antibodies specific to HNA-1a, -1b and
-2a have been described, are commercially available, and
have been used to phenotype neutrophils using flow cy-
tometry. This method is faster and easier, since the assay
can be done with the whole blood instead of isolated
neutrophils.
Genotyping assays to HNA-1a, -1b, -1c, -4a and -5a
have been developed. The characterization of the genes
encoding the HNA-1 antigens has allowed for the devel-
opment of genotyping assays for these antigens (Bux et
al. 1995, Kissel et al. 2000). HNA-1a, HNA-1b and
HNA-1c are encoded by FCGR3B*1, FCGR3B*2 and
FCGR3B*3, respectively. FCGR3B*1 and FCGR3B*2
differ at 5 nucleotides, one of which is silent. One nu-
cleotide differs between FCGR3B*2 and FCGR3B*3.
Although distinguishing single nucleotide polymorph-
isms is usually simple, genotyping for FCGR3B alle-
les is complicated by the high degree of homology bet-
ween FCGR3B and the gene that encodes FcγRIIIa,
FCGR3A. Among the 5 nucleotides that differ between
FCGR3B*1 and FCGR3B*2, FCGR3A is the same as
FCGR3B*1 at 3 nucleotides and the same as FCGR3B*2
at 2 nucleotides (Stroncek 2004). As a result most lab-
oratories, including ours, have employed PCR-SSP to
distinguish FCGR3B alleles (Fig. 1).
Fig. 1 – Example of HNA-1a, -1b genotyping determination by PCR-
SSP. The human growth hormone PCR product (428 bp) is present in
all reactions. (A) Lane 1 represents the 50 bp DNA ladder; Lanes 2
and 4: 118 bp PCR product obtained with HNA-1a primers; Lanes 5
and 7: 171 bp PCR product obtained with HNA-1b primers; Lanes 2
and 3: HNA-1a (+/+) homozygous person; Lanes 4 and 5: HNA-1a
(+/–) heterozygous subject; and Lanes 6 and 7 show a HNA-1b (+/+)
homozygous person; Lane 8 represents the negative control. (B) Lane
1: 50 bp DNA ladder; Lane 2: PCR-SSP positive for the FCGR3B*3
allele (HNA-1c); Lane 3: HNA-1c negative reaction; Lane 4: negative
control (Kuwano et al. 2000).
Methods to genotype neutrophil antigens HNA-4a
and -5a have been described (Simsek et al. 1996). Both
of these polymorphisms are due to a single nucleotide
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polymorphism. HNA-4a is due to a single nucleotide
substitution in the αM subunit of the β2 integrin, G302A,which predicts an Arg61His amino acid polymorphism.
HNA-5a is the result of a single nucleotide substitution
in the αL subunit of the β2 integrin, G2466C, which pre-dicts an Arg766Thr amino acid polymorphism. A variety
of methods can be used to type these alleles. A PCR-
SSP method is being used to type HNA-4a (Clague et al.
2003). HNA-5a can be typed using a PCR-SSP method
or, alternatively by a PCR-RFLP method described by
our group (Cardone et al. 2006) (Fig. 2).
Fig. 2 – Example of PCR-RFLP method and typical results of HNA-
5a genotyping. (A) Region (201 bp) in the genomic DNA, in which
the HNA-5a polymorphism is located, was amplified by PCR. The
sizes of the fragments produced by digestion with Bsp12861 are
shown. (B) Typical RFLP patterns Bsp12861-treated PCR product.
Lane 1: homozygous HNA-5a (+/+); Lane 2: heterozygous HNA-
5a (+/–); Lane 3: homozygous HNA-5a (–/–); Lane 4: not digested;
Lane M: 50 bp DNA ladder (Cardone et al. 2006).
Although the molecular basis of HNA-2a has al-
ready been described, HNA-2a genotyping methods
are not available, yet. The HNA-2a-negative phenotype
is due to CD177 mRNA splicing defects (Kissel et al.
2002). The CD177 mRNA from people with HNA-
2a-negative neutrophils contains additional sequences of
varying length that are homologous to CD177 intron se-
quences. However, no mutations have been detected in
the CD177 introns or exons from people with a nega-
tive phenotype. It may be possible to distinguish the
HNA-2a-positive from HNA-2a-negative phenotypes by
analyzing neutrophil CD177 mRNA for accessory se-
quences, but working with mRNA is much more diffi-
cult than working with DNA, and no laboratory is cur-
rently analyzing granulocyte mRNA to assess HNA-2a
antigen expression.
Because the gene encoding HNA-3a has not been
identified, no genotyping assays is available for this
antigen.
NEUTROPHIL ANTIBODIES
Screening for neutrophil antibodies remains technically
challenging. No single technique has thus far been shown
to consistently detect all clinically relevant granulocyte
antibodies.
The assays used to detect neutrophil antibodies are
GAT, GIFT or flow cytometry, and monoclonal anti-
body immobilization of granulocyte antigens (MAIGA).
In the GAT, antibodies cause neutrophils to actively ag-
glutinate (McCullough et al. 1988). It is a very reliable
assay, but less sensitive than other methods. The GAT
can detect antibodies to HNA-1, -2, -3, -4, and -5 anti-
gens, and it is the assay that can best identify antibodies
specific for HNA-3a.
In the microscopic GIFT, antigen-antibody reac-
tions are detected using fluorescence-conjugated second-
ary antibodies and a fluorescent microscope (McCul-
lough et al. 1988). Strong reactions are readily distin-
guished, but considerable training is required to distin-
guish weak reactions from background staining. Testing
for neutrophil antibodies with flow cytometry is the same
as the GIFT, except that neutrophils are evaluated with a
flow cytometer rather than a fluorescence microscope.
The MAIGA assay allows the detection of antibod-
ies to specific neutrophil membrane glycoproteins (Bux
et al. 1993). It can be used to detect antibodies specific
to HNA-1a, -1b, and -1c antigens on FcγRIIIb (CD16),
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HNA-2a on NB1gp (CD177), HNA-4a on complement
component C3bi receptor (CR3 or CD11b), and HNA-
5a on leukocyte function antigen-1 (LFA-1 or CD11a).
The use of neutrophils from panels of donors with
known HNA-1 phenotypes allows the identification of
antibodies specific to HNA-1a, -1b, and -1c. In addition,
antibodies that are directed to FcγRIIIb, but are not spe-
cific to HNA-1 antigens, are sometimes detected. The
MAIGA assay permits the recognition of antibodies to
specific neutrophil glycoproteins even when antibodies
to HLA antigens are present.
Because the gene encoding HNA-3a has not been
identified, recombinant technology cannot be used to
produce HNA-3a antigen. As a result, most laborato-
ries are using intact neutrophils for antibody screening
assays. Unfortunately, neutrophils have a short life span,
so fresh neutrophils must be prepared from fresh whole
blood using density gradient separation. Patient sera
are tested against panels of neutrophils prepared from
donors with known phenotypes to distinguish antibod-
ies with different specificities. The presence of HLA an-
tibodies can make the detection of neutrophil antibod-
ies difficult. HLA-specific antibodies can be separated
from neutrophil-specific antibodies by absorbing serum
with platelets (Sachs et al. 2005). Alternatively, mono-
clonal antibody capture assays can be used to test for
antibodies specific to neutrophil membrane glycopro-
teins. Mammalian cell expression systems have been
used to express HNA-1a, HNA-1b and HNA-2a, and
these can be used to assess antibodies in flow cytome-
try, but these cells are not commercially available.
CONCLUSIONS
During the last years, considerable progress has been
made in the characterization of granulocyte antigens.
Glycoprotein location of the antigens allowed the de-
velopment of the antigen-specific MAIGA. Elucidation
of their molecular basis now makes genotyping by PCR-
SSP possible. However, our understanding of the bio-
chemical and molecular nature of neutrophil antigens is
still incomplete and many questions remain: the clinical
significance of HNA-5 is not known, characterization of
the HNA-1 group is not yet complete, detailed descrip-
tion of the HNA-2 antigen is ongoing, and characteriza-
tion of the HNA-3a antigen is just beginning.
There are many barriers to neutrophil antibody test-
ing, including limited availability of reagent, lack of
commercially available test kits, and the need to use
fresh neutrophils. However, neutrophil antibodies re-
main clinically important and there are only few labo-
ratories specialized in granulocyte immunology; there-
fore, not all cases of alloimmune neutropenia are proba-
bly investigated. Further studies in the field of neutrophil
immunology will improve our diagnostic tools, and will
consequently facilitate the prevention and management
of transfusion reactions and immune diseases caused by
neutrophil antibodies.
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RESUMO
Os aloantígenos de neutrófilos estão associados a várias con-
dições clínicas como neutropenias imunes, insuficiência pul-
monar relacionada à transfusão (TRALI), refratariedade à
transfusão de granulócitos, e reações transfusionais febris. Na
última década, foi observado considerável progresso na carac-
terização dos aloantígenos envolvidos nestas condições clíni-
cas. Atualmente sete antígenos estão incluídos em cinco sis-
temas de antígenos de neutrófilo humano (HNA). Os antígenos
HNA-1a, HNA-1b e HNA-1c foram identificados como for-
mas polimórficas do receptor FcγRIIIb (CD16b), codificados
por três alelos. Recentemente, a estrutura primária do antígeno
HNA-2a foi elucidada e a glicoproteína carreadora do antígeno
foi identificada como um membro da superfamília Ly-6/uPAR
e designada como CD177. O antígeno HNA-3a está localizado
em uma glicoproteína de 70-90 kDa, entretanto sua base mole-
cular ainda é desconhecida. Finalmente, os antígenos HNA-4a
e HNA-5a são resultantes de mutações de um único nucleotí-
deo nas subunidades αM (CD11b) andαL (CD11a) das molécu-
las de adesão de leucócitos (β2 integrinas). A caracterizaçãomolecular e bioquímica dos antígenos neutrofílicos permitiu a
expansão das ferramentas diagnósticas pela introdução de téc-
nicas de genotipagem e imunoensaios para a identificação de
anticorpos. Novos estudos envolvendo a imunologia de granu-
lócitos serão de grande valor para a prevenção e tratamento de
reações transfusionais e doenças imunes causadas por aloanti-
corpos de neutrófilos.
Palavras-chave: antígenos de neutrófilos, transfusão sanguí-
nea, aloimunização, reação transfusional, neutropenia.
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